Dr James Pang, Research Fellow
Turner Institute for Brain and Mental Health, Monash University
VICTORIA, AUSTRALIA
Bench Side Story continues with a Research Fellow at the Turner Institute for Brain and Mental Health, at Monash University in Melbourne, Victoria, Australia.
Dr James Pang received his PhD in Physics from the University of Sydney and completed his postdoctoral training in the Brain Modelling Group at QIMR Berghofer Medical Research Institute (Brisbane, Australia). He is currently a Research Fellow at the Turner Institute for Brain and Mental Health, School of Psychological Sciences. His research employs a multidisciplinary approach that combines biophysical models, neuroimaging, and connectivity to better understand the mechanisms of brain function in health, disease, and across species.
-
Trials in treating STIs, vaccines and lipid lowering medications
Since joining Paratus Clinical Research in 2022, Dr Pi Lip Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
-
RESEARCH IMPACT: 35 years of kids’ health research
The Kids Research Institute Australia is one of the largest and most successful medical research institutes in Australia. The Institute has created a blueprint that brings together community, researchers, practitioners, policy makers and funders, who share our vision to improve the health and wellbeing of children through excellence in research. In November 2025, The Kids Research Institute Australia celebrated 35 years of bold ideas, groundbreaking research, and the people who find answers to the big questions about better health outcomes for children and families.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
